A Total of 630 Million Yen in Drug for Malaria, Tuberculosis, … and Diagnostics for Malaria

September 30, 2019

Malaria remains a major global heath burden with as much as a third of the global population at risk of disease. Importantly, it is the leading cause of death for children under five, especially in Sub-Saharan Africa. The malaria elimination and eradication effort has stalled in recent years and the World Health Organization Strategic Advisory Group on Malaria Eradication, has renewed the call for new, innovative tools to overcome the current limitations of our current tools.  

With this 1.3M in funding, Oasis Diagnostics and a cadre of  leaders in the diagnostics fields (CellFree Sciences Co. Ltd., ERADA Technology Alliance Ltd, Frontier Institute Co., Ltd.,  The University of Florida) are able to move forward to design a totally new system to address the malaria epidemic: A rapid, point of care, saliva diagnostic utilizing new markers for detection.

A Total of 630 Million Yen in Drug for Malaria, Tuberculosis, … and Diagnostics for Malaria

Oasis Diagnostics is slated to handle the Design and production of saliva collection device, lateral flow strip and lateral flow strip cassettes and for field evaluation and WHO pre-qualification.

See the original press release here: GHIT - Press Releases